BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioMarin excels in Q4 with record revenues and gene therapy launch

BioMarin Pharmaceutical reported strong financial results in Q4 2022, achieving revenue growth, profitability, and successful introduction of the ROCTAVIAN gene therapy for hemophilia A.
The company's performance highlights its R&D capabilities, market positioning, and strategic readiness for upcoming product launches, positioning BioMarin for continued growth and innovation.
While facing challenges in reimbursement processes and regulatory requirements, BioMarin has opportunities to drive revenue expansion, market penetration, and address unmet medical needs through its innovative pipeline.

BioMarin reports strong Q1 earnings, eyes blockbuster status for ROCTAVIAN

BioMarin Pharmaceuticals had a robust Q1 2023, focusing on revenue growth, profitability, and commercial readiness for key drug launches. While facing challenges in Germany, the company is optimistic about the potential of ROCTAVIAN and VOXZOGO in driving future growth.

BioMarin excels in Q2 with record revenues and treatment milestones

BioMarin's strong Q2 performance, driven by record revenues and product demand, positions the company for growth.
Challenges like supply issues and site readiness are being addressed, while opportunities in new programs and markets are promising.
Overall, BioMarin's focus on compliance, expansion, and pipeline development sets a positive trajectory for future success.

BioMarin reports strong Q3 revenue growth, eyes Roctavian expansion

BioMarin's Q3 performance showed revenue growth driven by Voxzogo, with strong expectations for 2024 revenue.
New CEO Alexander Hardy is set to continue the core strategy, focusing on Roctavian's global launch and Voxzogo's growth potential.
Challenges include delays in Roctavian's takeoff and supply constraints for Voxzogo, but efforts are underway to address these issues.
Opportunities lie in Roctavian's revenue contribution, Voxzogo's U.S. growth potential, and leveraging CNP for stature improvements.

BioMarin posts robust Q4 earnings, eyes expansion in gene therapy

BioMarin Pharmaceutical delivered strong financial results in Q4 2023, driven by revenue growth and increased earnings per share. The company's focus on high-impact medicines and gene therapy expertise positions it well for future growth.
While facing challenges related to analyst inquiries and market adoption of key products like Roctavian and Voxzogo, BioMarin remains committed to innovation and optimizing its business model.
Opportunities lie in expanding product reach, maximizing shareholder value through strategic capital allocation, and driving innovation in transformative programs. BioMarin's long-term strategy and growth potential remain promising.

BioMarin reports record revenue, focuses on key assets for growth

BioMarin Pharmaceutical's Q1 2024 performance reflects strong revenue growth and financial stability, driven by key product demand.
While facing challenges such as revenue impact and supply constraints, the company's strategic focus on key assets and cost reduction initiatives bode well for future growth.
Opportunities lie in expanding Voxzogo's market reach, optimizing manufacturing capabilities, and maintaining a competitive edge in innovative treatments.

BioMarin Pharmaceuticals reports record revenue and profitability outlook for 2024

BioMarin Pharmaceuticals delivered strong financial performance in Q2 2024, driven by robust revenue growth and strategic decisions. The company's focus on profitability, expansion of key treatments, and progress in R&D highlight a promising outlook. Addressing analyst inquiries and leveraging upcoming events can further enhance investor confidence and market positioning.

BioMarin reports record Q3 revenues, eyes long-term growth targets

BioMarin Pharmaceuticals showcased robust financial performance and raised full-year guidance.
The company remains optimistic about its long-term growth prospects and is committed to defending its IP.
Strategic focus on expanding global reach and driving growth in enzyme therapies portfolio.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares in this biotech company are down considerably from where they were this summer, but the stock looks ready to take off again.

Is Now A Good Time To Buy BioMarin Stock?

Avid Technology

II-VI Incorporated

Intel

Ultra Clean

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Intel and BioMarin.

Top Wall Street analysts back these stocks as earnings season kicks off

Shares of BioMarin Pharmaceuticals Inc. tumbled 6.6% in trading on Monday, the day after the company shared positive findings from a Phase 3 clinical trial evaluating the experimental drug Roctavian as a treatment for adults with severe hemophilia A. The Food and Drug Administration in August requested two years of follow-up data about the drug, a decision that effectively pushed back the possibility of approval to November 2021.

BioMarin's stock tumbles 6% after sharing data about experimental hemophilia A drug

BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients with hemophilia A.

BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy

SAN RAFAEL, Calif., Jan. 10, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe...

BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set

Cree

Firm also upped FibroGen stake in December

Primecap Curbs Holdings of Cree, BioMarin Pharmaceutical

Alexion Pharma

ALXN vs. BMRN: Which Stock Is the Better Value Option?

ALXN or BMRN: Which Is the Better Value Stock Right Now?

Alkermes

Ionis Pharma

Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over 2020, partly due to Covid-19 related disruptions of the health care industry.

BioMarin, Alkermes, Ionis: Are These Health Care Stocks Set To Outperform In 2021?

Amarin Corporation Plc

Biopharma deal-making is expected to pick up in 2021 after its slump in 2020, with a good example being AstraZeneca's (AZN) nearly $40 billion purchase of Alexion Pharmaceuticals (ALXN), which was announced on Dec. 12. Industry observers are already predicting that, after the down year that was 2020, M&A activity will return to pre-Covid heights, according to an article in FiercePharma.

With Alexion Off the Board, Amarin and Biomarin Are Attractive Acquisition Targets

Duke Energy

Enterprise Products Partners

Simon Property Group

Molson Coors Brewing

VMware

As markets flirt with record highs, there's more talk about overvalued stocks. However, it's time to consider undervalued stocks.

7 Undervalued Stocks That Could Soar in 2021

Deciphera Pharmaceuticals

uniQure

REGENXBIO

We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.

4 Biotechs That Could Be Potential Acquisition Targets in 2021

bluebird bio

Eli Lilly and Co. (LLY) recently showed its commitment to gene therapy when it signed a deal that could be worth $2.6 billion with Precision BioSciences Inc. (DTIL).

Bluebird Bio, Biomarin Tabbed as Top Acquisition Targets

Bristol-Myers

Eli Lilly

McKesson

Regeneron Pharmaceuticals

With 2020 almost over and the new year just two short weeks away, many investors are resetting for what could be a volatile 2021.

Goldman Sachs Adds Pharmaceutical Giant to Conviction List of Top Stocks to Buy

BioDelivery Sciences

Catalyst Pharmaceuticals

Innoviva

Novavax

Vertex Pharmaceuticals

Vaxart

Voyager Therapeutics

These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.

Top Biotech Stocks for Q1 2021

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?

Why Is BioMarin (BMRN) Up 6.1% Since Last Earnings Report?

New York, New York--(Newsfile Corp. - November 24, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between February 28, 2020 and August 18, 2020, inclusive (the "Class Period"), of the important November 24, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for BioMarin investors under the federal securities laws.To join the BioMarin class action, go...

FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important November 24 Deadline in Securities Class Action - BMRN

LOS ANGELES--(BUSINESS WIRE)---- $BMRN #BMRN--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against BioMarin Pharmaceutical Inc.

DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

NEW ORLEANS, Nov. 23, 2020 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until November 24, 2020 to file lead plaintiff applications in a securities class action lawsuit...

BIOMARIN 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN

New York, New York--(Newsfile Corp. - November 23, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) alleging that the Company violated federal securities laws.Class Period: February 28, 2020 and August 18, 2020Lead Plaintiff Deadline: November 24, 2020Learn more about your recoverable losses in BMRN:

BMRN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 24, 2020 in the Class Action Filed on Behalf of BioMarin Pharmaceutical Inc. Limited Shareholders

Los Angeles, California--(Newsfile Corp. - November 23, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ: BMRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 28, 2020 and August 18, 2020,...

DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - November 23, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of BioMarin Pharmaceutical Inc. ("BioMarin") (NASDAQ: BMRN) between February 28, 2020 and August 18, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Northern District of California. To get more...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 24, 2020 - BMRN

NEW ORLEANS--(BUSINESS WIRE)--ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until November 24, 2020 to file lead plaintiff applications in a securities class action lawsuit against BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN), if they purchased the Company's securities between February 28, 2020 and August 18, 2020, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California. Get

BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until November 24, 2020 to file lead plaintiff applications in a securities class action lawsuit against BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN), if they purchased the Company's securities between February 28, 2020 and August 18, 2020, inclusive (the “Class Period”). This action is pending in the United State

BIOMARIN 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN

New York, New York--(Newsfile Corp. - November 20, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between February 28, 2020 and August 18, 2020, inclusive (the "Class Period"), of the important November 24, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for BioMarin investors under the federal securities laws.To join the BioMarin class action, go...

BMRN FINAL DEADLINE: ROSEN, A RESPECTED LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important Tuesday Deadline in Securities Class Action - BMRN

New York, New York--(Newsfile Corp. - November 20, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ: BMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired BioMarin securities between February 28, 2020 and August 18, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting...

BMRN Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Shareholders of Class Action and Lead Plaintiff Deadline: November 24, 2020

News for BioMarin Pharmaceutical Stock (BMRN)